Matrix Global Advisors
  • Home
  • About
  • News
  • Reports
  • Contact
  • Follow
  • Follow
New MGA White Paper Examines Consequences of Regulatory Uncertainty for Employee Ownership

New MGA White Paper Examines Consequences of Regulatory Uncertainty for Employee Ownership

Oct 2, 2023 | Analysis

In a new white paper, Alex Brill details the consequences of regulatory uncertainty for businesses and provides a close look at the ongoing uncertainty facing companies owned by ESOPs. 

MGA Releases White Paper on Role of PBMs in US Drug Pricing Debate

MGA Releases White Paper on Role of PBMs in US Drug Pricing Debate

Sep 26, 2023 | Analysis

MGA latest white paper, by CEO Alex Brill, looks at the role of pharmacy benefit managers (PBMs) in the US prescription drug market.

MGA’s Latest: A Look at Community Health Centers

MGA’s Latest: A Look at Community Health Centers

Jun 8, 2023 | Analysis

MGA’s state-by-state analysis of Community Health Centers’ economic impact.

MGA’s Latest Work Examining Digital Health Tools

MGA’s Latest Work Examining Digital Health Tools

May 24, 2023 | Analysis

MGA has released a new report today for the Coalition for Affordable Prescription Drugs (CAPD), “Patent Thickets and Lost Drug Savings.”

New MGA Analysis of the Adalimumab Biosimilars Market in the United States

New MGA Analysis of the Adalimumab Biosimilars Market in the United States

Feb 21, 2023 | Analysis, Press Releases

The Biosimilars Council released the following statement in response to the new MGA report authored by Alex Brill and Christy Robinson.

New Report from MGA Examines the One-Year Cost Savings Lost Due to Patent Thickets

New Report from MGA Examines the One-Year Cost Savings Lost Due to Patent Thickets

Jan 26, 2023 | Analysis

MGA has released a new report today for the Coalition for Affordable Prescription Drugs (CAPD), “Patent Thickets and Lost Drug Savings.”

« Older Entries
Next Entries »
  • Analysis (53)
  • Books (3)
  • Commentary (15)
  • Events (21)
  • Interviews (60)
  • News (55)
  • Op-Eds (97)
  • Press Releases (4)
  • Testimony (21)
  • How Pharmaceutical Tariffs Will Affect US Health Care Costs
    How Pharmaceutical Tariffs Will Affect US Health Care CostsSeptember 26, 2025
  • Quantifying the economic impact of healthcare distributors
    MGA Releases New Report Quantifying the Economic Impact of Healthcare DistributorsSeptember 17, 2025
  • Unsung Hero of the OBBBA
    The Unsung Hero of the OBBBA: Permanent ExpensingAugust 20, 2025
  • Alex Brill Interviewed by Biosimilars Review & Report
    Alex Brill Interviewed by Biosimilars Review & ReportAugust 6, 2025
  • Medicare Price Negotiations and Drug Competition
    MGA Releases New White Paper on Medicare Price Negotiations and Drug CompetitionJuly 14, 2025
  • effects of 304B
    The 340B Program’s Negative Impact on Pharmaceutical InnovationJune 5, 2025
  • a conversation on tax reform
    A Conversation with House Ways and Means Committee Chairman Jason Smith on Tax ReformMarch 5, 2025
  • US Biosimilars Market
    New MGA Paper Identifies Barriers to US Biosimilar Success in the Second DecadeMarch 5, 2025
  • Congress on the Brink of Disrupting the PBM Market
    Congress on the Brink of Disrupting the PBM MarketJanuary 27, 2025
  • Raising the Salt Cap Would Increase Tax Complexity
    Raising the Salt Cap Would Increase Tax ComplexityJanuary 13, 2025
© Copyright 2022 Matrix Global Advisors | Design By DreamBig Creative
MGA
  • Home
  • About
  • News
  • Reports
  • Contact